Chongqing Zhifei Biological Products Co Ltd
SZSE:300122

Watchlist Manager
Chongqing Zhifei Biological Products Co Ltd Logo
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Watchlist
Price: 28.22 CNY -5.21% Market Closed
Market Cap: 67.7B CNY
Have any thoughts about
Chongqing Zhifei Biological Products Co Ltd?
Write Note

Gross Margin
Chongqing Zhifei Biological Products Co Ltd

25%
Current
36%
Average
63.9%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
25%
=
Gross Profit
11.7B
/
Revenue
46.7B

Gross Margin Across Competitors

Country CN
Market Cap 67.6B CNY
Gross Margin
25%
Country FR
Market Cap 6T USD
Gross Margin
0%
Country US
Market Cap 312.7B USD
Gross Margin
67%
Country US
Market Cap 158.3B USD
Gross Margin
60%
Country US
Market Cap 116.2B USD
Gross Margin
86%
Country US
Market Cap 112.4B USD
Gross Margin
78%
Country US
Market Cap 94.1B EUR
Gross Margin
76%
Country AU
Market Cap 133.6B AUD
Gross Margin
52%
Country US
Market Cap 81.3B USD
Gross Margin
87%
Country US
Market Cap 39.3B EUR
Gross Margin
75%
Country NL
Market Cap 34.8B EUR
Gross Margin
89%
No Stocks Found

Chongqing Zhifei Biological Products Co Ltd
Glance View

Market Cap
67.6B CNY
Industry
Biotechnology

Chongqing Zhifei Biological Products Co., Ltd., founded in 1992, has swiftly ascended to become a key player in the Chinese biopharmaceutical landscape, primarily focusing on the development, manufacturing, and commercialization of vaccines and diagnostic products. The company operates with a vision to address pressing public health challenges, and it has established an impressive portfolio that includes vaccines for diseases like hepatitis, influenza, and COVID-19. With a robust research and development (R&D) foundation, Zhifei has secured multiple partnerships and collaborations, further bolstering its innovation pipeline and expanding its market reach. This strategic positioning within China's burgeoning biopharmaceutical sector highlights the company’s commitment to quality and safety, aligning closely with the growing national emphasis on health and disease prevention. For investors, Zhifei represents not just a stake in a successful vaccine manufacturer, but also an opportunity to participate in a transformative phase of public health management in China and beyond. The company’s recent advancements in vaccine technology and its ability to rapidly pivot in response to global health emergencies—exemplified by its expedited COVID-19 vaccine development—underscore its agility and competitive edge in a high-growth market. As the demand for advanced biological products continues to rise globally, Zhifei’s solid financial foundations, coupled with government support for the biopharmaceutical industry, position it as a compelling investment with the potential for substantial long-term returns. The confluence of innovation, strong governmental backing, and a commitment to improving public health makes Chongqing Zhifei a noteworthy candidate for investors looking to tap into the evolving healthcare landscape.

Intrinsic Value
46.22 CNY
Undervaluation 39%
Intrinsic Value
Price

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
25%
=
Gross Profit
11.7B
/
Revenue
46.7B
What is the Gross Margin of Chongqing Zhifei Biological Products Co Ltd?

Based on Chongqing Zhifei Biological Products Co Ltd's most recent financial statements, the company has Gross Margin of 25%.